Market Closed -
Warsaw S.E.
11:55:45 2024-04-26 am EDT
|
5-day change
|
1st Jan Change
|
67
PLN
|
-1.47%
|
|
-4.42%
|
+14.53%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
375.3
|
904.9
|
1,505
|
1,522
|
1,074
|
1,230
|
-
|
-
|
Enterprise Value (EV)
1 |
375.3
|
843
|
1,588
|
1,659
|
1,074
|
1,418
|
1,463
|
1,634
|
P/E ratio
|
28
x
|
47
x
|
101
x
|
48.8
x
|
15.4
x
|
17.6
x
|
28.5
x
|
18
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
3.57
x
|
6.35
x
|
4.77
x
|
3.66
x
|
3.05
x
|
3.13
x
|
2.43
x
|
2.08
x
|
EV / Revenue
|
3.57
x
|
5.92
x
|
5.03
x
|
3.99
x
|
3.05
x
|
3.61
x
|
2.9
x
|
2.76
x
|
EV / EBITDA
|
-
|
25.5
x
|
18.7
x
|
14.8
x
|
14.6
x
|
15.7
x
|
11.9
x
|
10.7
x
|
EV / FCF
|
-
|
58.7
x
|
26.5
x
|
177
x
|
-
|
-74.6
x
|
-24.4
x
|
-61.9
x
|
FCF Yield
|
-
|
1.7%
|
3.77%
|
0.57%
|
-
|
-1.34%
|
-4.09%
|
-1.62%
|
Price to Book
|
-
|
5.75
x
|
7.65
x
|
5.8
x
|
-
|
4.16
x
|
3.63
x
|
2.9
x
|
Nbr of stocks (in thousands)
|
15,971
|
18,355
|
18,355
|
18,355
|
18,355
|
18,355
|
-
|
-
|
Reference price
2 |
23.50
|
49.30
|
82.00
|
82.90
|
58.50
|
67.00
|
67.00
|
67.00
|
Announcement Date
|
3/26/20
|
3/30/21
|
3/31/22
|
3/30/23
|
3/27/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
105.2
|
142.5
|
315.7
|
415.8
|
351.9
|
392.8
|
505.3
|
591.8
|
EBITDA
1 |
-
|
33.1
|
85.04
|
112.4
|
73.71
|
90.23
|
123
|
152.4
|
EBIT
1 |
-
|
19.57
|
57.55
|
44.78
|
16.75
|
34.8
|
67.28
|
88.3
|
Operating Margin
|
-
|
13.74%
|
18.23%
|
10.77%
|
4.76%
|
8.86%
|
13.31%
|
14.92%
|
Earnings before Tax (EBT)
1 |
-
|
18.85
|
21.07
|
40.21
|
67.2
|
22.8
|
52.9
|
84.5
|
Net income
1 |
-
|
18
|
14.9
|
30.31
|
69.88
|
18.4
|
43.1
|
68.4
|
Net margin
|
-
|
12.63%
|
4.72%
|
7.29%
|
19.86%
|
4.68%
|
8.53%
|
11.56%
|
EPS
2 |
0.8400
|
1.050
|
0.8120
|
1.700
|
3.800
|
3.800
|
2.350
|
3.730
|
Free Cash Flow
1 |
-
|
14.35
|
59.95
|
9.376
|
-
|
-19
|
-59.9
|
-26.4
|
FCF margin
|
-
|
10.07%
|
18.99%
|
2.25%
|
-
|
-4.84%
|
-11.85%
|
-4.46%
|
FCF Conversion (EBITDA)
|
-
|
43.37%
|
70.49%
|
8.34%
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
79.75%
|
402.34%
|
30.93%
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/26/20
|
3/30/21
|
3/31/22
|
3/30/23
|
3/27/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
---|
Net sales
1 |
81.55
|
93.01
|
95.02
|
103.4
|
109.1
|
108.3
|
91.81
|
89.14
|
84.18
|
86.84
|
83.3
|
EBITDA
1 |
22.75
|
27.1
|
16.71
|
28.56
|
29.74
|
26.46
|
19.1
|
21.22
|
16.96
|
16.43
|
15.65
|
EBIT
1 |
5.127
|
-
|
7.858
|
7.65
|
14.73
|
14.53
|
4.275
|
5.386
|
3.317
|
3.768
|
4.9
|
Operating Margin
|
6.29%
|
-
|
8.27%
|
7.4%
|
13.51%
|
13.42%
|
4.66%
|
6.04%
|
3.94%
|
4.34%
|
5.88%
|
Earnings before Tax (EBT)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net income
1 |
-2.32
|
8.147
|
4.894
|
-
|
8.993
|
12.7
|
2.447
|
7.875
|
-4.272
|
63.83
|
3.7
|
Net margin
|
-2.84%
|
8.76%
|
5.15%
|
-
|
8.25%
|
11.73%
|
2.67%
|
8.83%
|
-5.07%
|
73.5%
|
4.44%
|
EPS
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/24/21
|
3/31/22
|
5/31/22
|
9/16/22
|
11/9/22
|
3/30/23
|
5/30/23
|
9/27/23
|
11/15/23
|
3/27/24
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
82.8
|
138
|
-
|
188
|
233
|
404
|
Net Cash position
1 |
-
|
61.9
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
0.9738
x
|
1.225
x
|
-
|
2.088
x
|
1.898
x
|
2.65
x
|
Free Cash Flow
1 |
-
|
14.4
|
59.9
|
9.38
|
-
|
-19
|
-59.9
|
-26.4
|
ROE (net income / shareholders' equity)
|
-
|
19.1%
|
24.5%
|
13.2%
|
-
|
5%
|
12.2%
|
13.4%
|
ROA (Net income/ Total Assets)
|
-
|
11.6%
|
12.3%
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
154.8
|
121.2
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
-
|
8.570
|
10.70
|
14.30
|
-
|
16.10
|
18.40
|
23.10
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
15
|
27.5
|
79.8
|
-
|
43.2
|
50.2
|
97.4
|
Capex / Sales
|
-
|
10.53%
|
8.72%
|
19.19%
|
-
|
10.98%
|
9.93%
|
16.46%
|
Announcement Date
|
3/26/20
|
3/30/21
|
3/31/22
|
3/30/23
|
3/27/24
|
-
|
-
|
-
|
Average target price
71.28
PLN Spread / Average Target +6.39% Consensus |
1st Jan change
|
Capi.
|
---|
| +14.53% | 304M | | +1.51% | 42.75B | | +49.22% | 41.61B | | +8.57% | 41.34B | | -12.36% | 26.59B | | +8.92% | 25.49B | | -25.13% | 18.12B | | +29.17% | 12.24B | | -3.12% | 11.76B | | +6.35% | 11B |
Other Biotechnology & Medical Research
|